Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation.
Camphausen
Kevin
K
Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA. camphauk@mail.nih.gov
Scott
Tamalee
T
Sproull
Mary
M
Tofilon
Philip J
PJ
D000107:Acetylation; D000818:Animals; D001549:Benzamides / Q000494:pharmacology*; D014408:Biomarkers, Tumor; D001706:Biopsy; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D056572:Histone Deacetylase Inhibitors; D006657:Histones / Q000378:metabolism*; D006801:Humans; D008214:Lymphocytes / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D011471:Prostatic Neoplasms / Q000378:metabolism; D011725:Pyridines / Q000494:pharmacology*; D011836:Radiation Tolerance; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology*; D013997:Time Factors
D001549:Benzamides; D014408:Biomarkers, Tumor; D056572:Histone Deacetylase Inhibitors; D006657:Histones; D011725:Pyridines; D011838:Radiation-Sensitizing Agents; C118739:entinostat